Last update: Oct. 11, 2017
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
A synthetic polypeptide of 4 amino acids (l-alanine, l-glutamic, l-lysine and l-tyrosine), similar to myelin which is indicated in recurrences of multiple sclerosis (Ziemssen 2001).
Its high molecular weight makes it unlikely it will be excreted in breast milk and due to its protein nature it would be destroyed in the stomach of the infant, not absorbed, so its oral bioavailability is practically zero, except in premature babies and in the immediate neonatal period, where there may be greater intestinal permeability (2016 Almas, Cree 2013).
No problems have been observed in breastfeeding infants for periods ranging from 1 to 12 months whose mothers were taking glatiramer (Fragoso 2014, Hellwig 2012 and 2011, Fragoso 2010).
Glatiramer injected subcutaneously is hydrolyzed locally in amino acids and short peptides, so there are no appreciable levels of glatiramer in plasma. Severe side effects are unusual.
For some authors (Fragoso 2014) glatiramer would be the best multiple sclerosis disease-modifying drug to take during breastfeeding. One in 10 neurologists prescribe it during breastfeeding (Coyle 2004).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM